

INTRODUCTION

Sharing the responsibility of prostate cancer risk reduction **S91**
 L. Klotz, Y. Fradet, L. Goldenberg, S. Tanguay

REVIEWS

Diagnosis and management of benign prostatic hyperplasia in primary care **S92**
 S. Tanguay, M. Awde, G. Brock, R. Casey, J. Kozak, J. Lee, J.C. Nickel, F. Saad

The burden of prostate cancer in Canada **S102**
 Y. Fradet, L. Klotz, J. Trachtenberg, A. Zlotta

The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? **S109**
 L. Goldenberg, A. So, N. Fleshner, R. Rendon, D. Drachenberg, M. Elhilali

Gleason grading controversies: what the chemoprevention trials have taught us **S115**
 L. Klotz, D. Drachenberg, Y. Fradet, F. Saad, J. Trachtenberg, A. Zlotta

Publications Mail Agreement no. 41387051. Return undeliverable Canadian copies to *CUAJ*, 1155 University, Suite 1303, Montréal QC H3B 3A7; journal@cua.org.

Numéro de convention poste-publications 41387051. Retourner toutes copies canadiennes non livrées au *JAUC*, 1155 rue Université, Bureau 1303, Montréal, QC H3B 3A7; journal@cua.org.

USPS #024-122. USPS periodical postage paid at Champlain, NY. Return other undeliverable copies to IMS of NY, 100 Walnut St., #1, PO Box 1518, Champlain NY 12919-1518.

ISSN 1911-6470

This supplement is made possible through a non-restrictive educational grant by GlaxoSmithKline.